821 related articles for article (PubMed ID: 20621900)
1. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
[TBL] [Abstract][Full Text] [Related]
2. Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
Yusen RD; Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Chen M; Deslandes B; Turpie AG
Thromb Haemost; 2013 Dec; 110(6):1152-63. PubMed ID: 24085227
[TBL] [Abstract][Full Text] [Related]
3. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
[TBL] [Abstract][Full Text] [Related]
5. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Turpie AG; Wildgoose P; Yusen RD
J Thromb Thrombolysis; 2006 Aug; 22(1):31-8. PubMed ID: 16786230
[TBL] [Abstract][Full Text] [Related]
6. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Mebazaa A; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Merli G; Schellong SW; Spyropoulos AC; Tapson VF; De Sanctis Y; Cohen AT
Circulation; 2014 Jul; 130(5):410-8. PubMed ID: 24970782
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin and mortality in acutely ill medical patients.
Kakkar AK; Cimminiello C; Goldhaber SZ; Parakh R; Wang C; Bergmann JF;
N Engl J Med; 2011 Dec; 365(26):2463-72. PubMed ID: 22204723
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.
Turpie AG; Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Chen M; Yusen RD;
Stroke; 2013 Jan; 44(1):249-51. PubMed ID: 23117723
[TBL] [Abstract][Full Text] [Related]
9. Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
Amin AN; Girard F; Samama MM
Thromb Haemost; 2010 Nov; 104(5):955-61. PubMed ID: 20838741
[TBL] [Abstract][Full Text] [Related]
10. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
[TBL] [Abstract][Full Text] [Related]
12. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
Ann Intern Med; 2010 Jul; 153(1):I-50. PubMed ID: 20621897
[No Abstract] [Full Text] [Related]
14. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
Fuji T; Ochi T; Niwa S; Fujita S
J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
[TBL] [Abstract][Full Text] [Related]
15. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
17. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
Fanikos J; Rao A; Seger AC; Piazza G; Catapane E; Chen X; Goldhaber SZ
Am J Med; 2011 Dec; 124(12):1143-50. PubMed ID: 22114828
[TBL] [Abstract][Full Text] [Related]
20. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
